Medgend Icon

Ledgend of Medicine







discontinued


Velosulin FDA Approved Drugs

AFREZZA [Insulin Recombinant Human]
RX
-
12 units/inh (inhalation powder)
4 units/inh (inhalation powder)
8 units/inh (inhalation powder)
MannkindApr 17, 2015
  • Administration of a composition comprising insulin complexed with a diketopiperazine..
  • Administration of a composition comprising insulin complexed with microparticles of a diketopiperazine..
  • Administration of fdkp microparticles comprising insulin..
  • Method of aerosolizing/deagglomerating an insulin dry powder for use in treating diabetes mellitus via oral inhalation using an inhaler with a cartridge containing the insulin dry powder..
  • Method of controlling glycemia in diabetics by administering an initial dose of insulin-fdkp with a meal; determining blood glucose level 1-2 hrs after and administering a supplemental dose of insulin-fdkp if postprandial glucose level is >140 mg/dl.
  • Method of delivering to a patient with diabetes mellitus in a single inhalation, greater than 75% of a dry powder dose comprising insulin and fumaryl diketopiperazine using a high resistance to flow dry powder inhaler..
  • Pulmonary administration of a compisition comprising insulin bound to a diketopiperazine..
  • Pulmonary administration of a composition comprising insulin bound to a complexing agent..
  • Pulmonary administration of an insulin composition comprising fdkp at the beginning of a meal to a patient also being treated with a long-acting insulin..
  • Treatment of a patient having diabetes mellitus with a prandial rapid acting insulin..
  • Treatment of diabetes mellitus with an inhaled insulin to improve glycemic control using a dry powder inhalation system comprising an inhaler, a cartridge and a dry powder medicament comprising insulin in a single inhalation.
  • Treatment of patient having diabetes mellitus via oral inhalation of fdkp microparticles comprising insulin.
  • Use of an inhaler to administer dry powder medicament.
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
LillyOct 28, 1982
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

HUMULIN R PEN [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
LillyAug 6, 1998
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

NOVOLIN R [Insulin Recombinant Human]
OTC
-
100 units/ml (injection injectable)
Novo Nordisk IncJun 25, 1991
efficacy
0.0  (0)
side effects
0.0  (0)
danger
0.0  (0)

UNK

WARNING: Consult a licensed physician in the appropriate field for medical treatment and drug prescription. Do not self medicate.